Table 5 Comparison between AML subgroups regarding demographic, clinical data and hematological parameters at diagnosis
Demographic data, clinical data and hematological data | Non-responder AML cases with high normalized METTL3 gene expression (n = 25) | Responder AML cases with low normalized METTL3 gene expression (n = 15) | Significance | |
|---|---|---|---|---|
Test | p value | |||
Gender | ||||
Female | 13 (52.0%) | 5 (33.3%) | χ2 = 1.320 | 0.251 |
Male | 12 (48.0%) | 10 (66.7%) | ||
HSM | ||||
Yes | 23 (92.0%) | 9 (60.0%) | χ2 = 6.000 | 0.014* |
No | 2 (8.0%) | 6 (40.0%) | ||
Age (years) | ||||
Mean ± SD | 43.20 ± 18.44 | 39.80 ± 16.31 | t = 0.347 | 0.560 |
Range | 18–76 | 20–63 | ||
TLC | ||||
Median (IQR) | 40 (1.9–70) | 31.9 (2–75) | z = 1.681 | 0.203 |
HB | ||||
Mean ± SD | 7.69 ± 1.45 | 6.84 ± 1.81 | t = 2.665 | 0.111 |
Range | 4.00–10.4 | 3.30–9 | ||
PLTs | ||||
Median (IQR) | 19 (12–89) | 34 (11–55) | z = 2.446 | 0.126 |
BM blasts% | ||||
Median (IQR) | 75 (72–85) | 85 (48–88) | z = 2.124 | 0.153 |